Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.

International journal of molecular sciences - 29 Sept 2022

Watanabe Kazunori, Nakamura Toru, Kimura Yasutoshi, Motoya Masayo, Kojima Shigeyuki, Kuraya Tomotaka, Murakami Takeshi, Kaneko Tsukasa, Shinohara Yoshihito, Kitayama Yosuke, Fukuda Keito, Hatanaka Kanako C, Mitsuhashi Tomoko, Pittella-Silva Fabio, Yamaguchi Toshikazu, Hirano Satoshi, Nakamura Yusuke, Low Siew-Kee

Abstract excerpt

Pancreatic cancer is one of the cancers with very poor prognosis; there is an urgent need to identify novel biomarkers to improve its clinical outcomes. Circulating tumor DNA (ctDNA) from liquid biopsy has arisen as a promising biomarker for cancer detection and surveillance. However, it is known that the ctDNA detection rate in resected pancreatic cancer is low compared with other types of cancer. In this study,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36232820
DOI: 10.3390/ijms231911521
PMCID: PMC9570468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.PMID 36232820Read ↗

[Progress of circulating tumor DNA in diagnosis and prognosis of pancreatic cancer].Semantic proximity Read ↗

Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations.Semantic proximity Read ↗

Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.Semantic proximity Read ↗

Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlationsSemantic proximity Read ↗

ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.Semantic proximity Read ↗

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinomaSemantic proximity Read ↗

A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.Semantic proximity Read ↗

Clinical applications and perspectives of circulating tumor DNA in gastric cancerSemantic proximity Read ↗

Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.Semantic proximity Read ↗

Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasisSemantic proximity Read ↗

Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.